Expansion of composition-of-matter and biomarker patents in the drug discovery pipeline
First written in FY2024-Q3. 5 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「The rogocekib substance patent has been registered in 51 countries, while patent applications relating to biomarker identification in solid tumors and combination use with already approved anticancer drugs remain under examination. For CTX-177, the substance patent has been registered in 17 countries and the process patent in １ country, while the patent relating to combination use with already approved anticancer drugs remains under examination. The substance patent has been registered in 50 countries for CTX-439, and in 50 countries for GCN2 following the addition of １ country.」
The number of countries in which the CTX-177 substance patent is registered increased to 17, and that for CTX-439 increased to 50. One country was also added for GCN2, bringing the total to 50, indicating progress in patent registrations across multiple pipelines. - FY2025-H1AdvancedAnnual report
「For the patents held by the Company, the rogocekib substance patent has been registered in 51 countries to date; the CTX-177 substance patent has been additionally registered in ４ countries and is now registered in 15 countries; the CTX-439 substance patent has been additionally registered in 45 countries and is now registered in 49 countries; and the GCN2 substance patent has been additionally registered in 20 countries and is now registered in 25 countries.」
The increase in the number of countries where substance patents for rogocekib, CTX-177, CTX-439 and GCN2 are registered, along with their current registration status, was disclosed. - FY2024RestatedAnnual report
「There is no guarantee that all patents currently pending and held by the company will be granted.」
The policy of pursuing patent applications and registrations covering multiple drug discovery targets and biomarkers remains in place, while the uncertainty surrounding registration is also noted. - FY2024-Q3First statedAnnual report
「Regarding patents, one additional country has been added for the CTX-712 substance patent, which is now registered in 50 countries. Three additional countries have been added for the MALT1 substance patent, which is now registered in 9 countries. One additional country has been added for the CTX-439 substance patent, which is now registered in 4 countries. The GCN2 substance patent is currently registered in 6 countries. For CTX-712, in addition to publication of a biomarker patent for solid tumors (WO2023/190967), a new patent application was filed in January 2024.」
The number of countries in which patents are registered increased across multiple pipelines, while a biomarker patent for CTX-712 was published and a new application was filed in January 2024.